Myocardial cytokine expression in dogs with systemic and naturally occurring cardiac diseases

American Journal of Veterinary Research

Volumn 74, Issue 3, 2013, Pages 408-416

  Fonfara, Sonja ^a,b   Hetzel, Udo ^a,c   Tew, Simon R ^a   Cripps, Peter ^a   Dukes McEwan, Joanna ^a   Clegg, Peter D ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b UNIVERSITY OF BRISTOL   (United Kingdom)

^c UNIVERSITY OF HELSINKI   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; GROWTH DIFFERENTIATION FACTOR 15; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 8; MESSENGER RNA; TRANSFORMING GROWTH FACTOR BETA1; TRANSFORMING GROWTH FACTOR BETA2; TRANSFORMING GROWTH FACTOR BETA3; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOG; FEMALE; GENDER; HEART DISEASE; HEART MUSCLE; HISTOLOGY; MALE; NONHUMAN; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 84874403608     PISSN: 00029645     EISSN: None     Source Type: Journal    
DOI: 10.2460/ajvr.74.3.408     Document Type: Article

References (45)

1. Anker SD, von Haehling S. Inflammatory mediators in chronic heart failure: an overview. Heart 2004;90:464-470.
2. Chen D, Assad-Kottner C, Orrego C, et al. Cytokines and acute heart failure. Crit Care Med 2008;36:S9-S16.
3. von Haehling S, Schefold JC, Lainscak M, et al. Inflammatory biomarkers in heart failure revisited: much more than innocent bystanders. Heart Fail Clin 2009;5:549-560.
4. Tamariz L, Hare JM. Inflammatory cytokines in heart failure: roles in aetiology and utility as biomarkers. Eur Heart J 2010;31:768-770.
5. Hedayat M, Mahmoudi MJ, Rose NR, et al. Proinflammatory cytokines in heart failure: double-edged swords. Heart Fail Rev 2010;15:543-562.
6. Siwik DA, Colucci WS. Regulation of matrix metalloproteinases by cytokines and reactive oxygen/nitrogen species in the myocardium. Heart Fail Rev 2004;9:43-51.
7. Castellano G, Affuso F, Di Conza P, et al. Myocarditis and dilated cardiomyopathy: possible connections and treatments. J Cardiovasc Med (Hagerstown) 2008;9:666-671.
8. Kaur K, Dhingra S, Slezak J, et al. Biology of TNFalpha and IL-10, and their imbalance in heart failure. Heart Fail Rev 2009;14:113-123.
9. Wei L. Immunological aspect of cardiac remodeling: T lymphocyte subsets in inflammation-mediated cardiac fibrosis. Exp Mol Pathol 2011;90:74-78.
10. Cheng X, Ding Y, Xia C, et al. Atorvastatin modulates Th1/ Th2 response in patients with chronic heart failure. J Card Fail 2009;15:158-162.
11. Kvakan H, Kleinewietfeld M, Qadri F, et al. Regulatory T cells ameliorate angiotensin II-induced cardiac damage. Circulation 2009;119:2904-2912.
12. Kempf T, Wollert KC. Growth differentiation factor-15: a new biomarker in cardiovascular disease. Herz 2009;34:594-599.
13. Kempf T, von Haehling S, Peter T, et al. Prognostic utility of growth differentiation factor-15 in patients with chronic heart failure. J Am Coll Cardiol 2007;50:1054-1060.
14. Strickland KN. Pathophysiology and therapy of heart failure. In: Tilley LP, Smith FWK, Oyama MA, et al, eds. Manual of canine and feline cardiology. 4th ed. St Louis: Saunders Elsevier, 2008;288-314.
15. Fonfara S, Hetzel U, Tew S, et al. Leptin expression in dogs with cardiac disease and congestive heart failure. J Vet Intern Med 2011;25:1017-1024.
16. Clements DN, Carter SD, Innes JF, et al. Analysis of normal and osteoarthritic canine cartilage mRNA expression by quantitative polymerase chain reaction. Arthritis Res Ther 2006;8:R158.
17. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 2001;25:402-408.
18. Fonfara S, Hetzel U, Tew S, et al. Expression of matrix metalloproteinases, their inhibitors, and lysyl oxidase in hearts from dogs with end-stage systemic and cardiac diseases. Am J Vet Res 2013;74:216-223.
19. Tidholm A, Jonsson L. Histologic characterization of canine dilated cardiomyopathy. Vet Pathol 2005;42:1-8.
20. Adamopoulos S, Kolokathis F, Gkouziouta A, et al. Cytokine gene polymorphisms are associated with markers of disease severity and prognosis in patients with idiopathic dilated cardiomyopathy. Cytokine 2011;54:68-73.
21. Aukrust P, Ueland T, Lien E, et al. Cytokine network in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 1999;83:376-382.
22. Kumar A, Paladugu B, Mensing J, et al. Nitric oxide-dependent and-independent mechanisms are involved in TNF-alphainduced depression of cardiac myocyte contractility. Am J Physiol Regul Integr Comp Physiol 2007;292:R1900-R1906.
23. Martin FL, McKie PM, Cataliotti A, et al. Experimental mild renal insufficiency mediates early cardiac apoptosis, fibrosis, and diastolic dysfunction: a kidney-heart connection. Am J Physiol Regul Integr Comp Physiol 2012;302:R292-R299.
24. Kalogeropoulos A, Georgiopoulou V, Psaty BM, et al. Inflammatory markers and incident heart failure risk in older adults: the Health ABC (Health, Aging, and Body Composition) study. J Am Coll Cardiol 2010;55:2129-2137.
25. Yu Q, Horak K, Larson DF. Role of T lymphocytes in hypertension-induced cardiac extracellular matrix remodeling. Hypertension 2006;48:98-104.
26. Roncarolo MG, Gregori S, Battaglia M, et al. Interleukin-10secreting type 1 regulatory T cells in rodents and humans. Immunol Rev 2006;212:28-50.
27. Krishnamurthy P, Rajasingh J, Lambers E, et al. IL-10 inhibits inflammation and attenuates left ventricular remodeling after myocardial infarction via activation of STAT3 and suppression of HuR. Circ Res 2009;104:e9-e18.
28. Miettinen KH, Lassus J, Harjola VP, et al. Prognostic role of pro-and anti-inflammatory cytokines and their polymorphisms in acute decompensated heart failure. Eur J Heart Fail 2008;10:396-403.
29. Briest W, Homagk L, Rassler B, et al. Norepinephrine-induced changes in cardiac transforming growth factor-beta isoform expression pattern of female and male rats. Hypertension 2004;44:410-418.
30. Aupperle H, Marz I, Thielebein J, et al. Expression of transforming growth factor-beta1,-beta2 and-beta3 in normal and diseased canine mitral valves. J Comp Pathol 2008;139:97-107.
31. Lim H, Zhu YZ. Role of transforming growth factor-beta in the progression of heart failure. Cell Mol Life Sci 2006;63:2584-2596.
32. Shah S, Qiao L. Resting B cells expand a CD4+CD25+Foxp3+ Treg population via TGF-beta3. Eur J Immunol 2008;38:2488-2498.
33. Li N, Bian H, Zhang J, et al. The Th17/Treg imbalance exists in patients with heart failure with normal ejection fraction and heart failure with reduced ejection fraction. Clin Chim Acta 2010;411:1963-1968.
34. Rosenkranz-Weiss P, Tomek RJ, Mathew J, et al. Gender-specific differences in expression of mRNAs for functional and structural proteins in rat ventricular myocardium. J Mol Cell Cardiol 1994;26:261-270.
35. Villari B, Campbell SE, Schneider J, et al. Sex-dependent differences in left ventricular function and structure in chronic pressure overload. Eur Heart J 1995;16:1410-1419.
36. Arshad A, Moss AJ, Foster E, et al. Cardiac resynchronization therapy is more effective in women than in men: the MADIT-CRT (Multicenter Automatic Defibrillator Implantation Trial with Cardiac Resynchronization Therapy) trial. J Am Coll Cardiol 2011;57:813-820.
37. Wess G, Schulze A, Butz V, et al. Prevalence of dilated cardiomyopathy in Doberman Pinschers in various age groups. J Vet Intern Med 2010;24:533-538.
38. Serfass P, Chetboul V, Sampedrano CC, et al. Retrospective study of 942 small-sized dogs: prevalence of left apical systolic heart murmur and left-sided heart failure, critical effects of breed and sex. J Vet Cardiol 2006;8:11-18.
39. Sivakumar P, Gupta S, Sarkar S, et al. Upregulation of lysyl oxidase and MMPs during cardiac remodeling in human dilated cardiomyopathy. Mol Cell Biochem 2008;307:169-167.
40. Brundel BJ, Melnyk P, Rivard L, et al. The pathology of atrial fibrillation in dogs. J Vet Cardiol 2005;7:121-129.
41. Khan R, Sheppard R. Fibrosis in heart disease: understanding the role of transforming growth factor-beta in cardiomyopathy, valvular disease and arrhythmia. Immunology 2006;118:10-24.
42. Hanna N, Cardin S, Leung TK, et al. Differences in atrial versus ventricular remodeling in dogs with ventricular tachypacing-induced congestive heart failure. Cardiovasc Res 2004;63:236-244.
43. Kim SK, Park JH, Kim JY, et al. High plasma concentrations of transforming growth factor-beta and tissue inhibitor of metalloproteinase-1. Circ J 2011;75:557-564.
44. Verheule S, Sato T, Everett T IV, et al. Increased vulnerability to atrial fibrillation in transgenic mice with selective atrial fibrosis caused by overexpression of TGF-beta1. Circ Res 2004;94:1458-1465.
45. Khan A, Moe GW, Nili N, et al. The cardiac atria are chambers of active remodeling and dynamic collagen turnover during evolving heart failure. J Am Coll Cardiol 2004;43:68-76.